The Quantellect read.As of Nov 19, 2026, 20 active firms cover Ultragenyx: 12 rate it Buy or better, 8 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $16.00 to $70.00 (about 4.4x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $30.79 sits 74% above the current $17.74. The rating mix has stayed broadly stable, with Buy-side ratings easing from 17 to 12 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.04 next quarter toward $1.43 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS20 active firms
Buy
Strong Buy00%
Buy1260%
Neutral840%
Sell00%
Strong Sell00%
Based on 20 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$30.79
+73.6% upside
Average target across 19 active firms as of Nov 19, 2026 vs $17.74 current
Highest Target$70.00
Average Target$30.79
Lowest Target$16.00
Detailed analyst forecasts for RARE
Showing 1–23 of 23 named analysts shown · 20 active firms in the rating projection
As of Nov 19, 2026, 12 of 20 active firms rate RARE a Buy (8 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
RARE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.04
Range $-0.45 – $0.63 · 3 analysts · -97% YoY
Next period, 3 analysts expect Ultragenyx to earn $-0.04 a share (range $-0.45 – $0.63), versus $-1.54 a year earlier. Full-year consensus is $-3.05, growing to $1.43 the year after.
REVENUE · NEXT QUARTER
$198.7M
Range $159.0M – $312.1M · 3 analysts · +46% YoY
Revenue is expected to reach $198.7M (range $159.0M – $312.1M), +46.1% year-over-year. Full-year consensus is $766.9M, rising to $973.2M next year.
Top analysts covering Ultragenyx
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RARE.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #10
Buy
$74.00+317.1% to target
Overall win rate
64%
+ Follow
#2
Laura Chico
Wedbush · Rank #55
Neutral
$22.00+24.0% to target
Overall win rate
46%
+ Follow
#3
Joel Beatty
Baird · Rank #71
Neutral
$16.00-9.8% to target
Overall win rate
50%
+ Follow
#4
Luca Issi
RBC Capital · Rank #76
Neutral
$19.00+7.1% to target
Overall win rate
49%
+ Follow
#5
Ed Arce
HC Wainwright & Co. · Rank #168
Buy
$95.00+435.5% to target
Overall win rate
44%
+ Follow
RARE stock forecast FAQ
What is RARE's average 12-month price target?+
The 19 active firms with a live target average $30.79 for Ultragenyx over the next 12 months, ranging from a $70.00 high to a $16.00 low, as of Nov 19, 2026.
Is RARE stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 20 active firms as of Nov 19, 2026, 12 rate it Buy or Strong Buy, 8 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for RARE?+
The Street-high target is $70.00 (Leerink Partners), and the Street-low is $16.00 (UBS). The average of all 19 active-firm targets is $30.79.
How many active Wall Street firms cover RARE?+
20 active firms have a recognized rating on Ultragenyx as of Nov 19, 2026, and 19 active firms carry a live 12-month price target.
Who is the most accurate analyst covering RARE?+
Among analysts who currently cover RARE, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #10). Their current call is Buy with a $74.00 target.
What is Ultragenyx's projected EPS for next quarter?+
The consensus estimate is $-0.04 per share (range $-0.45 – $0.63) across 3 analysts. Full-year EPS is projected at $-3.05, rising to $1.43 the following year.
How much revenue is Ultragenyx expected to report next quarter?+
Consensus revenue is $198.7M (range $159.0M – $312.1M). Full-year revenue is projected at $766.9M, growing to $973.2M next year.
Have analysts been upgrading or downgrading RARE lately?+
As of Nov 19, 2026, 12 of 20 active firms rate RARE a Buy (8 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RARE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.